Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

  1. Yu, J.
  2. Bai, Y.
  3. Cui, Z.
  4. Cheng, C.
  5. Ladekarl, M.
  6. Cheng, K.-C.
  7. Chan, K.S.
  8. Yarmohammadi, H.
  9. Mauriz, J.L.
  10. Zhang, Y.
Aldizkaria:
Journal of Gastrointestinal Oncology

ISSN: 2219-679X,  2078-6891

Argitalpen urtea: 2024

Alea: 15

Zenbakia: 3

Orrialdeak: 1072-1081

Mota: Artikulua

DOI: 10.21037/JGO-24-315 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus